About

Daniel Primavessy, PhD, studied Bioinformatics and Biotechnology at Saarland University (Saarbrücken, Germany) from 2003 to 2011 and completed his PhD from 2011 to 2017 at Philipps-University (Marburg,
Germany) on peptide encapsulation into polymeric nanoparticulate and microparticulate systems.

He worked for two years as a post doctoral researcher at Saarland University and two years in a contract research organisation focusing on pulmonary in vitro instruments. In 2021, he joined Midas Pharma. As Project Manager and Scientist, Dr Primavessy’s work focuses on the evaluation of pharmaceutical innovation projects in device and formulation technology and the development of pharmaceutical products.

Contributions

INJECTION

A NOVEL INSTRUMENT TO STREAMLINE COMBINATION PRODUCT DEVELOPMENT

Daniel Primavessy, Sigrid Saaler-Reinhardt, Katarzyna Maksymowicz and Marie Stockton introduce the Gx Inbeneo^® platform simulator. This tool supports pharmaceutical companies in bridging formulation and medical device development processes, reducing time to market for patient-centric combination products.

More contributions

INJECTION

GX INBENEO^® – DEVELOPING AN AUTOINJECTOR THAT RESPONDS TO THE CHALLENGES OF BIOLOGICS

Daniel Primavessy, Sigrid Saaler-Reinhardt, Katarzyna Maksymowicz and Marie Stockton, Marketing Manager discuss how the Gx Inbeneo^® autoinjector from Gerresheimer was purpose designed to provide an effective, easy-to-use solution for the subcutaneous self-administration of sensitive biopharmaceuticals.